The French laboratory is preparing to request authorization from the regulatory authorities.
It’s time for relief at Sanofi. With almost a year late, his vaccine against the Covid is finally ready. The French laboratory and its British ally GSK, which manufactures the vaccine adjuvant, are preparing to submit their dossier to the European and American regulatory authorities. In the event of a green light, the first doses of the vaccine – which would be the sixth authorized in Europe after that of Novavax last December – could be available in the spring.
Read alsoSanofi confident despite the failure of its Covid vaccine
It remains to be seen what place this vaccine, initially planned for June 2021, will have in the arsenal of the fight against Covid: messenger RNA serums have won the bulk of the market (more than 80% in France for the vaccine of Pfizer/BioNTech), and the Omicron wave is currently in decline across the world. Denmark announced in early February the end of its vaccination campaign “no later than spring“. This vaccine – which is based on recombinant protein, a technology used in the vaccine against…
This article is for subscribers only. You have 80% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for 1€ the first month
Already subscribed? Login